Cipla Ltd has priced its generic version of remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, the Indian drugmaker said on Wednesday, making it among the lowest priced versions of the COVID-19 treatment available so far globally. Cipla had earlier said pricing would not exceed 5,000 rupees. On Tuesday, Sovereign Pharma, which is manufacturing and packaging the drug for Cipla, said it had dispatched the first batch.
Hetero Pharma starts supplying generic version of Remdesivir. Indian generic pharmaceutical giant Hetero announced that it was all set to deliver as many as 20,000 vials of ‘Covifor’ which costs 5,400 rupees per vial while Mylan prices Desrem at 4,800 rupees.
Meanwhile, Indian biotech firm Panacea Biotec Ltd said on Wednesday it remains on schedule to produce first production quantities of COVID-19 vaccine candidate by January 2021. It has set production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate.
As first, India’s Bharat Biotech and Zydus Cadila, listed as Cadila Healthcare Ltd, have received regulatory approvals to test their vaccine candidates in humans.
On May 29, Sun Pharmaceutical Industries has announced that it has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in COVID-19 patients. Nafamostat is approved in Japan for the improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC). Dilip Shanghvi, Managing Director, Sun Pharma said, “Sun Pharma is constantly evaluating potential targets that can be explored for treating Covid-19 patients. Nafamostat has shown promising data against SARS-CoV-2 virus in in-vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea. We believe it holds promise in the treatment of COVID-19 patients.”
Remdesivir’s developer, Gilead Sciences Inc , has priced the original version at $390 per 100 mg vial for wealthier nations while signing licensing deals with generic producers to make the treatment widely available. It was not immediately clear how many vials would be required for a full treatment course. Gilead has said a patient would typically need six vials of remdesivir for a five-day course.